Amir Agustin Estil-las

Dr. Amir Agustin Estil-las

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2024 in Neurology International
Verified
Journal Article
Open access
PDF file
AFAya Fadel
Aya Fadel
HHHussain Hussain
Hussain Hussain
RHRobert J. Hernandez
Robert J. Hernandez
ACAmanda Clichy-Silva
Amanda Clichy-Silva
AEAmir Agustin Estil-las
Amir Agustin Estil-las
AJArumugam Radhakrishnan Jayakumar
Arumugam Radhakrishnan Jayakumar
Neurosyphilis-induced dementia represents a severe manifestation of tertiary syphilis, characterized by cognitive and neuropsychiatric impairments. This condition arises from the progression of syphilis to the central nervous system, where the spirochete causes damage through invasion, chronic inflammation, and neurodegeneration. The pathophysiology involves chronic inflammatory responses, direct bacterial damage, and proteinopathies. Treponema pallidum triggers an inflammatory cascade, resulting in neuronal injury and synaptic dysfunction. Abnormal protein accumulations, including TAR DNA-binding protein 43 (TDP-43) and tau, contribute to neuronal loss and cognitive decline. Seizures, psychiatric symptoms, and motor deficits further complicate the progression of dementia. Diagnosis includes clinical assessment, cerebrospinal fluid analysis, and neuroimaging. Diagnostic tests include CSF-VDRL, FTA-ABS, and neuroimaging techniques such as MRI and PET scans, which help detect structural changes and confirm neurosyphilis. Management of neurosyphilis-induced dementia involves antibiotic therapy and psychotropic medications to address both infectious and symptomatic components. While penicillin remains the cornerstone of treatment, psychotropic agents, including haloperidol, risperidone, quetiapine, and divalproex sodium, can manage psychiatric symptoms. However, careful monitoring is required due to potential side effects and interactions with ongoing treatment. Overall, early diagnosis and comprehensive management are crucial for mitigating the cognitive and neuropsychiatric impairments associated with neurosyphilis-induced dementia.

4 August 2025 in Psychiatry International
Verified
Journal Article
Open access
PDF file
AEAmir Agustin Estil-las
Amir Agustin Estil-las
WSWilliam Sultan
William Sultan
CSCarla Sultan
Carla Sultan
MGMartena Grace
Martena Grace
MEMark Elias
Mark Elias
Kristal ArrautKristal Arraut
Kristal Arraut
Clozapine, a second-generation antipsychotic known for its effectiveness in treating resistant schizophrenia, is often linked with serious hematological side effects, particularly neutropenia and agranulocytosis. This review investigates the underlying pathophysiological mechanisms of clozapine-induced neutropenia (CIN) and agranulocytosis (CIA), outlines associated risk factors, and evaluates current clinical management strategies. Clozapine’s pharmacological profile, marked by its antagonism of dopamine D4 and serotonin receptors, contributes to both its therapeutic advantages and hematological toxicity. Epidemiological data show a prevalence of CIN and CIA at approximately 3.8% and 0.9%, respectively, with onset typically occurring within the first six months of treatment. Key risk factors include older age, Asian and African American ethnicity, female sex, and certain genetic predispositions. The development of CIN and CIA may involve bone marrow suppression and autoimmune mechanisms, although the exact processes remain partially understood. Clinical presentation often includes nonspecific symptoms such as fever and signs of infection, necessitating regular hematological monitoring in accordance with established guidelines. Management strategies include dosage adjustments, cessation of clozapine, and the administration of granulocyte colony-stimulating factors (G-CSF). Advances in pharmacogenomics show promise for predicting susceptibility to CIN and CIA, potentially improving patient safety. This review emphasizes the importance of vigilant monitoring and personalized treatment approaches to reduce the risks associated with clozapine therapy.

31 July 2025 in Cureus
Verified
Journal Article
Open access
PDF file
AEAmir Agustin Estil-las
Amir Agustin Estil-las
MGMartena Grace
Martena Grace
CACamelia Arsene
Camelia Arsene
JRJessie Gonzalez La Rosa
Jessie Gonzalez La Rosa
Dementia and cataracts are two leading causes of disability among the elderly population throughout the world. The relationship between both pathologies remains underrecognized. This paper explores the emerging evidence linking cataracts to cognitive decline and dementia, proposing that visual impairment may contribute to neurodegeneration. Popular hypotheses supporting these claims include circadian rhythm disruption, sensory deprivation, reduced social engagement, and increased cognitive load. Epidemiological data supports the co-prevalence of cataracts and dementia. Patients undergoing cataract removal have shown improved performance on cognitive assessments, suggesting that vision correction may enhance neural efficiency and quality of life; moreover, interventional studies demonstrate that cataract surgery not only improves visual impairment but may also slow cognitive deterioration. This paper also elucidates the clinical and public health implications of the integration of vision care into cognitive health strategies. The global dementia burden is projected to rise sharply in the coming decades; we propose that early intervention through cataract surgery may offer a cost-effective method to preserve cognitive function. Ultimately, identifying and treating visual impairment may serve as a crucial step toward delaying the progression of dementing illnesses.

22 August 2025 in Cureus
Verified
Journal Article
Open access
PDF file
AEAmir Agustin Estil-las
Amir Agustin Estil-las
MGMartena Grace
Martena Grace
CHChetna N. Hirani
Chetna N. Hirani
TVTanisha Vora
Tanisha Vora
CACamelia Arsene
Camelia Arsene
Diabetic striatopathy (DS) is a rare neurological complication of non-ketotic hyperglycemia. It is distinguished by the acute onset of hemichorea and hemiballismus, as well as distinct radiographic findings involving the contralateral basal ganglia. We present the case of a 61-year-old male patient with a history of poorly controlled diabetes mellitus who developed acute involuntary movements affecting the right upper and lower extremities. Computed tomography (CT) revealed a hyperdensity in the left basal ganglia, and T1 hyperintensity with mild diffusion-weighted imaging hyperintensities on MRI, consistent with DS. Patient history and laboratory analysis revealed diabetic medication non-compliance and a glycosylated hemoglobin (HbA1c) of 14% and a blood glucose level of 472 mg/dL, without evidence of ketosis. The patient was treated with insulin therapy, resulting in proper glycemic control and complete resolution of symptoms. This case underscores the importance of recognizing DS in patients with hyperglycemia and acute movement disorders, as timely diagnosis and metabolic correction can lead to full neurological recovery and prevent unnecessary interventions.

23 January 2025 in Cureus
Verified
Journal Article
Open access
PDF file
MGMartena Grace
Martena Grace
AEAmir Agustin Estil-las
Amir Agustin Estil-las
CACamelia Arsene
Camelia Arsene
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by aseptic, non-infectious skin lesions. This report details a case of PG in a 49-year-old woman with multiple comorbidities and limited access to healthcare resources. In the absence of standardized treatment protocols, the case illustrates the successful application of a multidisciplinary therapeutic approach combining surgical intervention with medical management using corticosteroids and immunomodulators. The report includes visual documentation of the treatment process and disease progression, providing a comprehensive timeline of clinical outcomes. Furthermore, it highlights the challenges of managing PG in resource-constrained settings, emphasizing the importance of consistent monitoring and proactive intervention to prevent complications.

6 February 2026 in The Columbia University Journal of Global Health
Verified
Journal Article
Open access
MGMartena Grace
Martena Grace
AEAmir Agustin Estil-las
Amir Agustin Estil-las
CACamelia Arsene
Camelia Arsene
Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the burden falling disproportionately on populations in low- and middle-income countries (LMICs), where access to timely screening is limited. Advances in artificial intelligence (AI) have enabled the development of automated DR screening tools with diagnostic accuracy comparable to expert graders, offering a potential solution to overcome some of the unique challenges LMICs face. This review examines the performance, global implementation, and unique barriers of AI-based DR screening in low-resource environments, focusing on five leading systems: IDx-DR, EyeArt, Medios AI, Google’s Automated Retinal Disease Assessment (ARDA), and SELENA+. Evidence shows these systems can increase detection rates, reduce referral delays, and improve access to care. However, their integration into healthcare faces unique challenges including data generalizability, infrastructure, regulation, and clinician and patient acceptance. Strategies such as federated learning, offline-capable devices, and easily-comprehensible AI may help overcome these barriers, enabling AI-driven screening to play a critical role in reducing vision loss from DR globally.